Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v8i3.123 |
Resumo: | Introduction: The positive impact of pharmacist-physician collaborative care has been reported in the international literature, although examples of this impact are limited in Portugal. We aim to underline the clinical added value for hypertensive patients that results from pharmacist-physician collaborations.Methods: A community trial was conducted at a Portuguese family health unit for 19 months. The intervention group was randomly selected from the global records and members of the group received pharmaceutical care in addition to physician care. The comparison group received only physician care. Both groups were comparable at the beginning of the study. In the intervention group, we analysed the hypertensive patients to evaluate the impact of pharmacist-physician collaboration on the patients’ blood pressure levels. This evaluation was performed by comparing the obtained blood pressure levels with the levels at baseline and between the groups.Results: A total of 17 patients with hypertension were enrolled in the pharmaceutical care programme, 12 of whom were female. The mean age was 68.50±3.26 years and, on average, each patient consumed 6.06±0.93 medicinal products. Thirteen patients were uncontrolled. Compared with the baseline, the intervention group achieved mean reductions of 28.85±5.90 mmHg (p < 0.0005) and 11.23±2.75 mmHg (p < 0.005) in their systolic and diastolic blood pressure, respectively. Considering the comparison group, improvements of 18.63±6.44 mmHg (p = 0.011) in systolic blood pressure and 9.03±2.63 mmHg ( p < 0.005) in diastolic blood pressure were observed.Conclusion: Pharmacist-physician collaborative care adds clinical value to the typical physician care provided to hypertensive patients within the context of a Portuguese family health unit. |
id |
RCAP_08a8ddd3245042b91f4e6da036aaa194 |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/123 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive PatientsImpacto Clínico de um Programa de Acompanhamento Farmacoterapêutico Implementado numa Unidade de Saúde Familiar: Resultados de uma Colaboração entre Farmacêutico e Médico no Tratamento de Doentes HipertensosIntroduction: The positive impact of pharmacist-physician collaborative care has been reported in the international literature, although examples of this impact are limited in Portugal. We aim to underline the clinical added value for hypertensive patients that results from pharmacist-physician collaborations.Methods: A community trial was conducted at a Portuguese family health unit for 19 months. The intervention group was randomly selected from the global records and members of the group received pharmaceutical care in addition to physician care. The comparison group received only physician care. Both groups were comparable at the beginning of the study. In the intervention group, we analysed the hypertensive patients to evaluate the impact of pharmacist-physician collaboration on the patients’ blood pressure levels. This evaluation was performed by comparing the obtained blood pressure levels with the levels at baseline and between the groups.Results: A total of 17 patients with hypertension were enrolled in the pharmaceutical care programme, 12 of whom were female. The mean age was 68.50±3.26 years and, on average, each patient consumed 6.06±0.93 medicinal products. Thirteen patients were uncontrolled. Compared with the baseline, the intervention group achieved mean reductions of 28.85±5.90 mmHg (p < 0.0005) and 11.23±2.75 mmHg (p < 0.005) in their systolic and diastolic blood pressure, respectively. Considering the comparison group, improvements of 18.63±6.44 mmHg (p = 0.011) in systolic blood pressure and 9.03±2.63 mmHg ( p < 0.005) in diastolic blood pressure were observed.Conclusion: Pharmacist-physician collaborative care adds clinical value to the typical physician care provided to hypertensive patients within the context of a Portuguese family health unit. Introdução: O impacto positivo da colaboração entre farmacêutico-médico para a saúde do doente está bem documentado na literatura internacional. Em Portugal, os exemplos de colaboração são limitados. Com este trabalho pretendemos sublinhar a mais-valia clínica da colaboração farmacêutico-médico em doentes hipertensos.Métodos: Ensaio comunitário desenvolvido numa unidade de saúde familiar portuguesa, durante 19 meses. O grupo de intervenção, selecionado aleatoriamente do ficheiro global, foi submetido a acompanhamento farmacoterapêutico pelo farmacêutico. O grupo de comparação recebeu apenas os cuidados médicos habituais. Ambos os grupos eram comparáveis à partida. Analisámos os doentes hipertensos para avaliar o impacto da colaboração farmacêutico-médico nos níveis de pressão arterial. A avaliação foi efetuada por comparação com o ponto de partida e entre os dois grupos.Resultados: Integraram o programa de acompanhamento farmacoterapêutico, 17 hipertensos, 12 do género feminino com idade média de 68,50±3,26 e um consumo médio de medicamentos de 6,06±0,93. Do total, 13 não estavam controlados. Comparando com o início, o grupo de intervenção reduziu, em média, 28,85±5,90 mmHg (p < 0,0005) na pressão arterial sistólica e 11,23±2,75 mmHg (p < 0,005) na diastólica. Na comparação entre grupos, registou-se uma redução de 18,63±6,44 mmHg (p = 0,011) na pressão arterial sistólica e de 9,03±2,63 mmHg (p < 0,005) na diastólica.Conclusão: A colaboração farmacêutico-médico em doentes hipertensos numa unidade de saúde familiar Portuguesa acrescentou mais-valia clínica aos cuidados de saúde habitualmente recebidos pelos doentes.Formifarma2016-09-14info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v8i3.123https://doi.org/10.25756/rpf.v8i3.123Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 8 No 3 (2016): July; 7-14Revista Portuguesa de Farmacoterapia; v. 8 n. 3 (2016): Julho; 7-142183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://revista.farmacoterapia.pt/index.php/rpf/article/view/123http://revista.farmacoterapia.pt/index.php/rpf/article/view/123/101Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessCondinho, MónicaSá, JorgeEliseu, ArquimínioFigueiredo, Isabel VitóriaSinogas, Carlos2023-09-01T04:33:37Zoai:ojs.farmacoterapia.pt:article/123Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:35.014967Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients Impacto Clínico de um Programa de Acompanhamento Farmacoterapêutico Implementado numa Unidade de Saúde Familiar: Resultados de uma Colaboração entre Farmacêutico e Médico no Tratamento de Doentes Hipertensos |
title |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients |
spellingShingle |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients Condinho, Mónica |
title_short |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients |
title_full |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients |
title_fullStr |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients |
title_full_unstemmed |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients |
title_sort |
Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients |
author |
Condinho, Mónica |
author_facet |
Condinho, Mónica Sá, Jorge Eliseu, Arquimínio Figueiredo, Isabel Vitória Sinogas, Carlos |
author_role |
author |
author2 |
Sá, Jorge Eliseu, Arquimínio Figueiredo, Isabel Vitória Sinogas, Carlos |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Condinho, Mónica Sá, Jorge Eliseu, Arquimínio Figueiredo, Isabel Vitória Sinogas, Carlos |
description |
Introduction: The positive impact of pharmacist-physician collaborative care has been reported in the international literature, although examples of this impact are limited in Portugal. We aim to underline the clinical added value for hypertensive patients that results from pharmacist-physician collaborations.Methods: A community trial was conducted at a Portuguese family health unit for 19 months. The intervention group was randomly selected from the global records and members of the group received pharmaceutical care in addition to physician care. The comparison group received only physician care. Both groups were comparable at the beginning of the study. In the intervention group, we analysed the hypertensive patients to evaluate the impact of pharmacist-physician collaboration on the patients’ blood pressure levels. This evaluation was performed by comparing the obtained blood pressure levels with the levels at baseline and between the groups.Results: A total of 17 patients with hypertension were enrolled in the pharmaceutical care programme, 12 of whom were female. The mean age was 68.50±3.26 years and, on average, each patient consumed 6.06±0.93 medicinal products. Thirteen patients were uncontrolled. Compared with the baseline, the intervention group achieved mean reductions of 28.85±5.90 mmHg (p < 0.0005) and 11.23±2.75 mmHg (p < 0.005) in their systolic and diastolic blood pressure, respectively. Considering the comparison group, improvements of 18.63±6.44 mmHg (p = 0.011) in systolic blood pressure and 9.03±2.63 mmHg ( p < 0.005) in diastolic blood pressure were observed.Conclusion: Pharmacist-physician collaborative care adds clinical value to the typical physician care provided to hypertensive patients within the context of a Portuguese family health unit. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-09-14 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v8i3.123 https://doi.org/10.25756/rpf.v8i3.123 |
url |
https://doi.org/10.25756/rpf.v8i3.123 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/123 http://revista.farmacoterapia.pt/index.php/rpf/article/view/123/101 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 8 No 3 (2016): July; 7-14 Revista Portuguesa de Farmacoterapia; v. 8 n. 3 (2016): Julho; 7-14 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129986199715840 |